Related Experiment Video
Updated: Mar 6, 2026

Methods to Study Mrp4-containing Macromolecular Complexes in the Regulation of Fibroblast Migration
Published on: May 19, 2016
Inactivation of ID4 promotes a CRPC phenotype with constitutive AR activation through FKBP52
Jugal Bharat Joshi1, Divya Patel1, Derrick J Morton1
1Center for Cancer Research and Therapeutic Development, Clark Atlanta University, GA, USA.
Abstract:
Castration-resistant prostate cancer (CRPC) is the emergence of prostate cancer cells that have adapted to the androgen-depleted environment of the prostate. In recent years, targeting multiple chaperones and co-chaperones (e.g., Hsp27, FKBP52) that promote androgen receptor (AR) signaling and/or novel AR regulatory mechanisms have emerged as promising alternative treatments for CRPC. We have shown that inactivation of inhibitor of differentiation 4 (ID4), a dominant-negative helix loop helix protein, promotes de novo steroidogenesis and CRPC with a gene expression signature that resembles constitutive AR activity in castrated mice. In this study, we investigated the underlying mechanism through which loss of ID4 potentiates AR signaling. Proteomic analysis between prostate cancer cell line LNCaP (L+ns) and LNCaP lacking ID4 (L(-)ID4) revealed elevated levels of Hsp27 and FKBP52, suggesting a role for these AR-associated co-chaperones in promoting constitutively active AR signaling in L(-)ID4 cells. Interestingly, protein interaction studies demonstrated a direct interaction between ID4 and the 52-kDa FK506-binding protein (FKBP52) in vitro, but not with AR. An increase in FKBP52-dependent AR transcriptional activity was observed in L(-)ID4 cells. Moreover, pharmacological inhibition of FKBP52-AR signaling, by treatment with MJC13, attenuated the tumor growth, weight, and volume in L(-)ID4 xenografts. Together, our results demonstrate that ID4 selectively regulates AR activity through direct interaction with FKBP52, and its loss, promotes CRPC through FKBP52-mediated AR signaling.
Insights
Loss of inhibitor of differentiation 4 (ID4) promotes castration-resistant prostate cancer (CRPC) by enhancing androgen receptor (AR) signaling through FKBP52. Targeting FKBP52-AR signaling may offer new CRPC treatments.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Castration-resistant prostate cancer (CRPC) involves prostate cancer adaptation to low androgens.
- Targeting chaperones and co-chaperones like Hsp27 and FKBP52 offers novel CRPC treatment strategies.
- Inhibitor of differentiation 4 (ID4) loss promotes de novo steroidogenesis and CRPC with constitutive androgen receptor (AR) activity.
Purpose of the Study:
- To investigate the mechanism by which ID4 loss potentiates AR signaling in CRPC.
- To elucidate the role of Hsp27 and FKBP52 in ID4-mediated AR regulation.
- To evaluate the therapeutic potential of targeting FKBP52-AR signaling in CRPC.
Main Methods:
- Proteomic analysis of LNCaP cells with and without ID4.
- In vitro protein interaction studies between ID4, FKBP52, and AR.
- Assessment of AR transcriptional activity in ID4-deficient cells.
- Pharmacological inhibition of FKBP52-AR signaling in L(-)ID4 xenografts.
Main Results:
- Loss of ID4 led to elevated levels of Hsp27 and FKBP52 in prostate cancer cells.
- ID4 directly interacts with FKBP52, but not AR.
- FKBP52-dependent AR transcriptional activity was increased in ID4-deficient cells.
- Pharmacological inhibition of FKBP52-AR signaling reduced tumor growth in xenografts.
Conclusions:
- ID4 selectively regulates AR activity via direct interaction with FKBP52.
- Loss of ID4 promotes CRPC by enhancing FKBP52-mediated AR signaling.
- Targeting FKBP52-AR signaling represents a potential therapeutic approach for CRPC.
Related Concept Videos
Regulation of the Unfolded Protein Response
Co-activators and Co-repressors
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
X-Inactivation
Restarting Stalled Replication Forks
Abnormal Proliferation

